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for the propensity score this remained signiﬁcantly higher (HR  2.93, 95% CI 1.42, 
6.02) for those with concurrent aspirin, but was non-signiﬁcant in those with no 
concurrent aspirin (HR  1.48, 95% CI 0.76, 2.89). In contrast, in the SCCS the rela-
tive incidence (RI) of GI hospitalisation for COX-2 s vs tNSAIDs was 0.73 (0.604, 
0.998) in those with no concurrent ulcer healing drugs. CONCLUSIONS: Traditional 
cohort analysis methods only weakly adjust for confounding, especially confounding 
by indication. Case-only designs give results more akin to trials. Interpretation still 
requires care as each design makes crucial assumptions.
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WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS: 
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OBJECTIVES: To estimate work productivity in Danish patients consulting primary 
care physicians with upper gastrointestinal (UGI) symptoms and the effect of acid-
suppressive therapy. METHODS: The RESPONSE study was a randomized, double-
blind, placebo-controlled primary care study focusing on proton pump inhibitor 
treatment of acid-related UGI symptoms. A secondary objective assessed improvement 
in productivity loss following 2 weeks of esomeprazole 40 mg once daily or placebo. 
Work productivity due to UGI symptoms was measured using the Work Productivity 
and Activity Impairment questionnaire speciﬁc for patients with UGI symptoms 
(WPAI : UGIS) and a Danish national average wage rate was applied to calculate the 
value of lost time. Treatment effect on work productivity loss was tested using 
Kolgomorov-Smirnov test. RESULTS: A total of 805 patients completed the study; 
423 patients reported being employed at baseline and were included in the analysis. 
The estimated total cost of average work productivity loss in the 7 days preceding 
contact with the physician was a316 (DKK 2355) per patient (95% conﬁdence interval 
[CI]: a277, a355). This was equivalent to 10.5 working hours/week, and increased 
with increasing severity of UGI symptoms at baseline. Of the total loss, absence from 
work contributed 2.2 hours/week (95% CI: 1.6, 2.8) and reduced productivity while 
at work (presenteeism) 8.3 hours/week (95% CI: 7.3, 9.3). After 2 weeks of treatment, 
the mean improvement in work productivity per week was signiﬁcantly higher for 
both absenteeism (1 hour vs. 0.1 hour, p  0.05) and presenteeism (5.3 hours vs. 4.3 
hours, p  0.05) in patients treated with esomeprazole vs placebo. The economic value 
of the incremental gain in productivity with esomeprazole vs. placebo was a45/week. 
CONCLUSIONS: The results indicate that acid-related UGI symptoms in Danish 
primary care patients represent a signiﬁcant economic burden in terms of lost produc-
tivity, which can be addressed with acid-suppressive therapy. Supported by AstraZen-
eca, Albertslund, Denmark.
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INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE 
TREATMENT OF PEPTIC ULCER BLEEDING (PUB)
Edwards SJ, Gray J, Borrill J
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OBJECTIVES: To evaluate the efﬁcacy of iv PPIs in treating PUB. METHODS: 
 Randomised controlled trials (RCTs) identiﬁed in a Cochrane systematic review of 
CENTRAL, EMBASE and MEDLINE (1996 to November 2004) were supplemented 
with an update to December 2008 and then searched for RCTs with consistent pre-
randomization endoscopic haemostatic treatment (EHT) that compared any iv PPI 
with either placebo (including no treatment) or a histamine-2-receptor antagonist 
(H2RA). Data on overall mortality, rebleeding, emergency surgery and further EHT 
were extracted and re-analysed if not analysed by intention-to-treat. Summary effect 
estimates (Relative Risk, RR) were calculated by meta-analysis using a ﬁxed-effects 
model by the Mantel-Haenszel method. Quality of RCTs included in the meta-analysis 
was judged based on an assessment of the method of randomisation and concealment 
of allocation. Sensitivity analysis was conducted using the DerSimonian and Laird 
random-effects model. RESULTS: Of the 251 papers identiﬁed, 10 were suitable to 
provide data for analysis (4 PPI vs H2RA; 6 PPI vs placebo). When compared with 
either an H2RA or placebo, PPIs signiﬁcantly reduced rebleeding (RR 0.53; 95% 
Conﬁdence Interval [CI]: 0.41–0.68; p  0.00001), emergency surgery (RR 0.58; 
95%CI: 0.43–0.79; p  0.0004) and further EHT (RR 0.49; 95%CI: 0.38–0.64; 
p  0.00001). There was a non-signiﬁcant reduction in overall mortality (RR 0.85; 
95%CI: 0.59–1.21; p  0.35), which became signiﬁcant when a single outlier trial was 
excluded in a post-hoc analysis (RR 0.68; 95%CI: 0.46–0.99; p  0.05). The trial 
was excluded based on imbalanced patient allocation: substantially more patients with 
previous PUB were randomised to the placebo arm, and surviving a prior PUB is 
associated with increased likelihood of surviving a subsequent PUB. The sensitivity 
analysis using a random-effects model provided results consistent with the primary 
analysis. CONCLUSIONS: Intravenous PPIs have signiﬁcant beneﬁts over treatment 
with an H2RA or placebo for PUB, which may include a signiﬁcant reduction in overall 
mortality.
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OBJECTIVES: To determine the clinical effectiveness of three anti-TNF-A agents 
(inﬂiximab, adalimumab, etanercept) in refractory Crohn’s dissease (CD). METHODS: 
An electronic literature search was conducted to identify randomized controlled trials 
(RCT) and observational studies on CD and anti-TNF-a drugs that were published 
from 1996–2008 using Medline, EMBASE, PubMed, Wiley’s Cochrane Library, and 
Thomson’s BIOSIS Previews. Websites of professional associations were also searched. 
A random effect pooled analysis was performed when tw0 or more comparable stuides 
were identiﬁed. RESULTS: Of 2557 citations identiﬁed, the publications related to 13 
RCTs and 7 observational studies met the inclusion criteria. All included RCTs had 
a methodological quality score (Jadad scale) of 3 or more. Included effectiveness trials 
were largely placebo-controlled. Findings indicate that inﬂiximab is effective in induc-
tion and maintenance of clinical response and remission in patients with luminal or 
ﬁstulizing CD who are resistant or refractory to conventional therapy. Inﬂiximab also 
reduces the need for surgical resection and hospitalization in CD. Adalimumab was 
shown to be effective for inducing and maintaining clinical remission in CD patients 
with secondary non-response to inﬂiximab or who are naive to anti-TNF-A drugs. No 
statistically signiﬁcant difference was observed between adalimumab and placebo in 
terms of ﬁstula improvement or remission rates. However, a signiﬁcantly higher rate 
of ﬁstula remission was reported when adalimumab was used as maintenance therapy 
in one study. A majority of CD patients re-established reduced response after inﬂix-
imab or adalimumab dose escalation. The results of this review showed that CD 
patients with secondary non-response to inﬂiximab could beneﬁt from adalimumab 
therapy. CONCLUSIONS: Inﬂiximab and adalimumab have shown a consistent 
 superiority to placebo in induction and maintenance of clinical remission, as well 
as in reducing the rates of surgery and hospitalization in refractory CD. CD patients 
who begin to lose their response to anti-TNF-A treatment could beneﬁt from dose 
escalation.
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OBJECTIVES: Prucalopride is a selective 5-HT    4 agonist, effective for treatment of 
chronic constipation, as demonstrated in three pivotal phase III trials and a trial in 
elderly patients. The aim of this study was to explore if baseline patient characteristics 
could predict efﬁcacy of prucalopride after four weeks treatment. Two efﬁcacy 
outcome measures were considered: R1) response deﬁned as an increase from baseline 
of q1 point in patient-reported satisfaction with treatment; R2) response deﬁned as 
an average of q3 spontaneous complete bowel movements (SCBM) per week. 
METHODS: Data from four trials were combined (n  1256). Univariate associations 
of baseline characteristics with response were investigated. Stepwise logistic regression 
was used to build a predictive model and classiﬁcation trees analysis (CTA) models 
were constructed on data from a random selection of two-thirds of the patients. The        
predictive value of the constructed model was evaluated on the remaining one-third 
using ROC-curve analysis. RESULTS: Univariate associations identiﬁed 4 covariates 
strongly associated with R1 (satisfaction with treatment, abdominal pain, laxative use, 
rectal symptoms) and 10 with R2 (SCBM, CBM, SBM, BM, fewer BM than you like, 
satisfaction with BM frequency and regularity, abdominal symptoms, laxative use, 
frequency of BM in preceding six months). The ﬁnal stepwise logistic regression 
models contained the same baseline covariates, whereas the CTA-models contained 
fewer covariates, but had a comparable predictive value (67% positive predictive 
value, 80% sensitivity and 41% speciﬁcity for R1 and 44% positive predictive value, 
17% sensitivity and 91% speciﬁcity for R2). CONCLUSIONS: Self-reported satisfac-
tion with treatment, symptoms, and laxative use at baseline has meaningful predictive 
value for response to treatment with prucalopride in patients with chronic 
constipation.
GASTROINTESTINAL DISORDERS – Cost Studies
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EVALUATION OF RESOURCE UTILIZATION AND ECONOMIC IMPACT 
OF RECURRENCE FOR INGUINAL HERNIA REPAIR PERFORMED WITH 
PHS DEVICE VERSUS POLYPROPYLENE MESH UNDER THE BRAZILIAN 
PRIVATE PAYER PERSPECTIVE
Bastide P, Pontes DAR, Negri MA
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OBJECTIVES: To evaluate the direct costs related to recurrence of inguinal hernia 
repair, in patients who underwent the surgery with PHS versus Polypropylene mesh, 
under the Brazilian private payer perspective. METHODS: A decision model was 
developed to assess the costs and resource usage for the recurrence of inguinal hernia 
repair with the PHS versus Polypropylene mesh under the private payer perspective, 
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based on Brazilian guidelines for HTA (Vianna, 2007). The study was based on clinical 
data published by AWAD 2007, showing PHS device has lower recurrence rate com-
pared to Polypropylene mesh (0.6% versus 2.7%, p  0.04) in 17 months. The recur-
rence rate was projected to 60 months (PHS 2.1%; Polyprolylene mesh 9.2%) to 
evaluate clinical and economic long-term impact. The average incidence rate of 2% 
for inguinal hernia was based on Brazilian specialist’s opinions. The econom impact 
of recurrence was calculated considering 200.000 patients. Procedure costs, hospital 
stay, devices costs and medical staff fees were obtained from Brazilian public lists 
(CBHMP 4a. ed., Boletim Proahsa and SIMPRO). According to local guidelines, 5% 
of discount rate was adopted. One-way sensitivity analysis was performed to verify 
the robustness of the results. RESULTS: According to the model, 108 patients will 
need reintervention in the Polypropylene mesh group versus 24 in the PHS group in 
17 months, representing 74% on reoperation reduction. In 60 months, 368 patients 
will need reintervention in the Polypropylene group versus 84 in the PHS, 77% reop-
eration reduction. There was a positive impact of recurrence in the PHS group of 
R$ 105,401 for a 17 months period (R$ 100,382 discounted) and R$ 355,821 for a 
60 months period (R$ 292,730 discounted). CONCLUSIONS: Findings suggest PHS 
as a safe and efﬁcient alternative for inguinal hernia repair when compared with 
Polypropylene mesh and can generate resource economy under the payer perspective 
in Brazil.
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OBJECTIVES: Opioid induced constipation (OIC) is an important adverse event in 
the management of patients with chronic pain. The aim of this project was to describe 
the current management (prevention, treatment, complications) and resource use of 
OIC in Belgium (B) and The Netherlands (NL), and to estimate to estimate the associ-
ated cost (societal perspective). METHODS: A 2-round Delphi panel was performed 
in a sample both of 24 general practitioners (GPs) (12 per country). Questions were 
related to current medical practice (medical treatment, tests and imaging, consulta-
tions, hospitalizations, treatment of complications and impact of OIC on work pro-
ductivity). Pain was deﬁned as persisting for at least three months and for which 
opioids were permanently administered. Costs were calculated by multiplying average 
resource use obtained from the Delphi panel with speciﬁc unit costs (ofﬁcial tariffs). 
RESULTS: The cost per day for prevention of OIC (before a ﬁrst episode (primary) 
or to prevent a new episode (secondary)) was respectively a1.33 and a2.13 for Belgium 
and The Netherlands. Respectively 68%/89% of the patients in Belgium/The Nether-
lands received primary laxative-prophylaxis (average duration per 3 months: 47 days 
(B) and 58 days (NL)). Secondary prophylaxis was given in 100% of the patients. The 
cost of a constipation-episode was 130a in Belgium, a102 in The Netherlands. The 
higher cost in Belgium was mainly due to higher cost for tests and treatment. Cost of 
complications (B: 8% of patients, NL: 12%) of OIC ranged in Belgium between a71 
(abdominal pain) and a1386 (rectal prolapse). Cost of complications in The Nether-
lands ranged between a23 (vomiting) and a410 (faecal impaction). Work absenteeism 
due to OIC and related complications resulted in a cost of a42 for Belgium and a128 
for The Netherlands. CONCLUSIONS: Management of OIC has an important eco-
nomic impact both in Belgium and The Netherlands, especially when complications 
occur.
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COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON  
PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR 
DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY
Borrill J, Edwards SJ, Gray J
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OBJECTIVES: To compare the cost-effectiveness of iv PPI (80 mg bolus followed by 
8 mg/h infusion for 72 h) in patients considered at risk of gastric or duodenal ulcer 
(peptic ulcer) rebleeding after therapeutic endoscopy. METHODS: A systematic 
review and mixed treatment comparison (WinBUGS) provided estimates of the relative 
risk of peptic ulcer rebleed, repeat endoscopy and emergency surgery with acute iv 
PPI using placebo as a common comparator. A decision analytic model was then used 
to determine the cost per quality adjusted life years (QALYs) gained for iv esomepra-
zole, iv pantoprazole and iv omeprazole. Patients with no rebleed received 28-day 
treatment with the respective oral PPI (esomeprazole 40 mg od, pantoprazole 40 mg 
od or omeprazole 20 mg od). Costs of medical and operative procedures were sourced 
from the National Schedule of Reference Costs (2007/08). Disutilities for repeat 
endoscopy and surgery were estimated from a published study that used time trade 
off interviews in adults with peptic ulcer disease. A 30-day time horizon was used. 
The analysis was conducted from the perspective of the UK National Health Service 
(NHS). Uncertainty was investigated through one way sensitivity analysis and proba-
bilistic Monte Carlo simulation. RESULTS: Intravenous esomeprazole was the pre-
ferred treatment strategy. Probabilistic Monte Carlo simulation indicated that, at a 
threshold of £20,000/QALY, there was a 66% probability that iv esomeprazole was 
the most cost-effective compared to 33% and 1% for iv omeprazole or iv pantopra-
zole, respectively. The NHS would need to adopt a cost-effectiveness threshold in 
excess of £65,000/QALY for iv omeprazole to be considered the most cost-effective 
treatment for this indication. CONCLUSIONS: Based on the current best available 
evidence, iv esomeprazole, the only European licensed iv PPI for the prevention of 
recurrent peptic ulcer bleed after therapeutic endoscopy, is the most cost-effective 
treatment option and represents good value for money for the NHS.
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BACKGROUND: Iron deﬁciency and anaemia (Hb-level      12 g/dl) is common in 
patients with inﬂammatory bowel disease (IBD). First line treatment for correcting 
iron deﬁciency is oral iron. In patients intolerant to oral iron, intravenous (IV) iron 
is recommended. OBJECTIVES: To evaluate incremental costs and effects (ICER) of        
IV iron compared to discontinuation of oral iron, in IBD patients intolerant to oral 
iron. METHODS: A micro-simulation model of the Hb-level and intravenous or oral          
iron treatment was developed using published data, a chart review of IBD patients 
and calibration. QALYs and costs for drug (including administration), transport and 
loss of production due to IV iron administration in an outpatient setting were esti-
mated using a one-year time frame with two relapses causing anaemia. At treatment 
start, patients are in relapse with a Hb-level of 10 g/dl and treated with oral iron. As        
they become intolerant, the model either switches them to IV iron or discontinues 
treatment. Sensitivity analyses were carried out with respect to initial Hb and number 
of relapses per year. RESULTS: In the base case, treatment with IV iron generates a 
QALY gain of 0.0334 at a cost of a1,530, i.e. an ICER of a45,800. A treatment start 
at lower initial Hb-levels generates higher QALY-gains and lower costs per QALY, 
e.g. a35,900 per QALY gained with an initial Hb-level of 9 g/dl. The ICER in patients 
with one relapse per year gain is a61,460, reﬂecting a high initial cost when determin-
ing appropriate iron treatment regimen. CONCLUSIONS: In a health care perspective,     
IV iron compared to oral iron is cost-effective in patients in relapse. In a societal 
 perspective, IV iron is cost-effective provided that 50% of the patients work 
during relapse.
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OBJECTIVES: Adherence to the prescribed treatment regimen is an important factor 
that impacts on the success of therapy in chronic hepatitis C. The aim of this study 
was to develop a cost-effectiveness analysis of a multidisciplinary support program 
(MSP) versus conventional treatment in a group of Hepatitis C (HC) patients. 
METHODS: A total of 278 naïve and mono-infected patients with HC were included 
in the study: 131 in Group 1 (MSP strategy) and 147 in Group 2 (conventional treat-
ment approach). All patients were treated with Peg-IFN-alfa-2a and Ribavirin. The 
MSP not only included hepatologists and nurses, but also, pharmacists, psychologists 
and assistants; additionally uniform patient education, open and ﬂexible visits schedul-
ing, continued evaluation of psychiatric risk and active medication were carried out. 
A decision-tree model was built to estimate the incremental cost-effectiveness ratio 
(ICER) of MSP vs. conventional control. Unitary costs of HC drugs and professionals 
were included. Effectiveness was measured in terms of sustained virological response 
(SVR), adherence was deﬁned as 80% dose administered. RESULTS: For genotypes 
1/4 (G-1/4), adherence was achieved in 92.4% of patients in group 1 and 69.3% in 
group 2 (p  0.0005), for genotypes 2/3 (G-2/3) adherence was achieved in 96.9% 
and 93.2% in groups 1 and 2 respectively (p  0.05). SVR differed in the two groups: 
66.7% in group 1 and 48.9% in group 2 for G-1/4 (p  0.03) and 87.7% and 81.4% 
for G-2/3 (p  0.05) for groups 1 and 2 respectively. Cost per SVR was higher in 
group 2 than in group 1 (a24,079 and a20,197 in G-1/4; a8,351 and a7,723 in G-2/3). 
The ICER was a9,533/SVR in G-1/4 patients and group 1 was dominant over group 
2 in G-2/3 patients. CONCLUSIONS: The MSP could improve the adherence to the 
HC treatment and therefore the virological response, and could be also a cost-effective 
strategy compared with the conventional approach.
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THE COST EFFECTIVENESS OF INFLIXIMAB IN THE TREATMENT OF 
ACUTE ULCERATIVE COLITIS PATIENTS IN SCOTLAND
Shore E
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OBJECTIVES: To estimate the cost effectiveness of inﬂiximab treatment among         
patients with severely active ulcerative colitis (UC) hospitalised with an acute exacer-
bation. METHODS: A decision analytic model was used to simulate the progression          
of hypothetical cohorts of patients with an exacerbation of UC receiving different 
treatment strategies, inﬂiximab, ciclosporin, standard care or surgical intervention. 
For extrapolation beyond the trial period, a Markov model was used. The relative 
risk of disease progression on different treatment alternatives was determined by an 
indirect comparison between clinical trial. The primary outcome was quality adjusted 
life years (QALYs) using EQ-5D estimates. A time horizon of one year was selected 
based on the decision problem and the availability of evidence. Costs and beneﬁts 
